Disease · MONDO_0005525
T-cell leukemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. T-cell leukemia. Diseases, record MONDO_0005525. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005525
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- T cell leukaemia (disease), T cell leukemia (disease), leukaemia (disease) of T cell, leukemia (disease) of T cell
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FORODESINE HYDROCHLORIDE | CHEMBL550755 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AZACITIDINE | CHEMBL1489 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VENETOCLAX | CHEMBL3137309 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RG-4733 | CHEMBL4297422 | Small molecule | Phase 1 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED | CHEMBL4297989 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets16
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| APH1A | Gamma-secretase | 1 | Gamma-secretase inhibitor | Phase 1 | https://conductscience.org/library/genes/51107 | Drugs and targets |
| APH1B | Gamma-secretase | 1 | Gamma-secretase inhibitor | Phase 1 | https://conductscience.org/library/genes/83464 | Drugs and targets |
| BCL2 | Apoptosis regulator Bcl-2 | 1 | Apoptosis regulator Bcl-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/596 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 other | Phase 1 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1786 | Drugs and targets |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | 1 | DNA (cytosine-5)-methyltransferase 3A inhibitor | Phase 2 | https://conductscience.org/library/genes/1788 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 1/2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IL15RA | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3601 | Drugs and targets |
| IL2RB | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-15 receptor | 1 | Interleukin-15 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3561 | Drugs and targets |
1 to 10 of 16
See all 16 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03905135 | Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies | Phase 1 | 8 | 2022-09-13 | Peripheral T-cell Lymphoma NOS, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma | AVELUMAB, INTERLEUKIN 15, RECOMBINANT NON-GLYCOSYLATED | Its record names the disease | ClinicalTrials.gov |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | Phase 1 | 129 | Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Medulloepithelioma, Childhood Mixed Glioma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Gonadotroph Adenoma, Pituitary Basophilic Adenoma, Pituitary Chromophobe Adenoma, Pituitary Eosinophilic Adenoma, Prolactin Secreting Adenoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Spinal Cord Neoplasm, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Pituitary Tumor, Recurrent/Refractory Childhood Hodgkin Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia, T-cell Large Granular Lymphocyte Leukemia, TSH Secreting Adenoma, Unspecified Childhood Solid Tumor, Protocol Specific | DEXAMETHASONE, RG-4733 | Its record names the disease | ClinicalTrials.gov | |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | Phase 2 | 100 | Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, Therapy-Related Acute Myeloid Leukemia | AZACITIDINE, VENETOCLAX | Its record names the disease | ClinicalTrials.gov | |
| NCT06345027 | Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) | Phase 1 | 78 | Leukemia, Myeloid, Acute, Leukemia, B-cell, Leukemia, T-Cell | CYCLOPHOSPHAMIDE, FLUDARABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00035022 | Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas | Phase 1/2 | 71 | Leukemia, Lymphocytic, Lymphoma | FORODESINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | Phase 1/2 | 29 | Leukemia, Mantle Cell Lymphoma, Myelofibrosis | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT00095381 | Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia | Phase 2 | 20 | Leukemia, T-Cell | FORODESINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01236586 | RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia | Phase 1 | 0 | Lymphoma, Brain Neoplasms, Sarcoma, Osteosarcoma, Wilm's Tumor | DEXAMETHASONE, RG-4733 | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: Number of Participants With a Dose-limiting Toxicity (DLT) | 1 of 6 | 1 of 2 | 8 | NCT03905135 | Trial comparisons |
Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 6 of 6 | 2 of 2 | 8 | NCT03905135 | Trial comparisons |
| Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: deaths from any cause | 3 of 6 | 0 of 2 | 8 | NCT03905135 | Trial comparisons |
| Dose Escalation - Dose Level 1, 1mcg/kg Interleukin-15 With 10 mg Avelumab vs Dose Level 2, 2mcg/kg Interleukin-15 With 10 mg Avelumab: serious adverse events | 6 of 6 | 0 of 2 | 8 | NCT03905135 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005525
GET https://conductscience.org/api/diseases/v1/MONDO_0005525/drugs